MRUS
Price
$41.70
Change
-$1.30 (-3.02%)
Updated
Apr 3, 04:59 PM (EDT)
Capitalization
2.97B
39 days until earnings call
XENE
Price
$30.71
Change
-$0.75 (-2.38%)
Updated
Apr 3 closing price
Capitalization
2.35B
39 days until earnings call
Ad is loading...

MRUS vs XENE

Header iconMRUS vs XENE Comparison
Open Charts MRUS vs XENEBanner chart's image
Merus
Price$41.70
Change-$1.30 (-3.02%)
Volume$11.58K
Capitalization2.97B
Xenon Pharmaceuticals
Price$30.71
Change-$0.75 (-2.38%)
Volume$904.03K
Capitalization2.35B
MRUS vs XENE Comparison Chart
Loading...
MRUS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
XENE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
MRUS vs. XENE commentary
Apr 04, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is MRUS is a Hold and XENE is a Hold.

Ad is loading...
COMPARISON
Comparison
Apr 04, 2025
Stock price -- (MRUS: $41.71 vs. XENE: $30.71)
Brand notoriety: MRUS and XENE are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: MRUS: 139% vs. XENE: 178%
Market capitalization -- MRUS: $2.97B vs. XENE: $2.35B
MRUS [@Biotechnology] is valued at $2.97B. XENE’s [@Biotechnology] market capitalization is $2.35B. The market cap for tickers in the [@Biotechnology] industry ranges from $299.64B to $0. The average market capitalization across the [@Biotechnology] industry is $2.21B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

MRUS’s FA Score shows that 1 FA rating(s) are green whileXENE’s FA Score has 1 green FA rating(s).

  • MRUS’s FA Score: 1 green, 4 red.
  • XENE’s FA Score: 1 green, 4 red.
According to our system of comparison, XENE is a better buy in the long-term than MRUS.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

MRUS’s TA Score shows that 5 TA indicator(s) are bullish while XENE’s TA Score has 4 bullish TA indicator(s).

  • MRUS’s TA Score: 5 bullish, 4 bearish.
  • XENE’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, MRUS is a better buy in the short-term than XENE.

Price Growth

MRUS (@Biotechnology) experienced а -6.97% price change this week, while XENE (@Biotechnology) price change was -10.88% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -8.91%. For the same industry, the average monthly price growth was -11.19%, and the average quarterly price growth was -14.86%.

Reported Earning Dates

MRUS is expected to report earnings on May 13, 2025.

XENE is expected to report earnings on May 13, 2025.

Industries' Descriptions

@Biotechnology (-8.91% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
MRUS($2.97B) has a higher market cap than XENE($2.35B). MRUS YTD gains are higher at: -0.820 vs. XENE (-21.658). MRUS (-269.6M) and XENE (-276.74M) have comparable annual earnings (EBITDA) . XENE has more cash in the bank: 627M vs. MRUS (537M). XENE has less debt than MRUS: XENE (9.02M) vs MRUS (9.91M). MRUS has higher revenues than XENE: MRUS (36.1M) vs XENE (0).
MRUSXENEMRUS / XENE
Capitalization2.97B2.35B127%
EBITDA-269.6M-276.74M97%
Gain YTD-0.820-21.6584%
P/E RatioN/AN/A-
Revenue36.1M0-
Total Cash537M627M86%
Total Debt9.91M9.02M110%
FUNDAMENTALS RATINGS
MRUS vs XENE: Fundamental Ratings
MRUS
XENE
OUTLOOK RATING
1..100
6665
VALUATION
overvalued / fair valued / undervalued
1..100
61
Fair valued
98
Overvalued
PROFIT vs RISK RATING
1..100
2937
SMR RATING
1..100
9794
PRICE GROWTH RATING
1..100
7983
P/E GROWTH RATING
1..100
1004
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

MRUS's Valuation (61) in the Biotechnology industry is somewhat better than the same rating for XENE (98). This means that MRUS’s stock grew somewhat faster than XENE’s over the last 12 months.

MRUS's Profit vs Risk Rating (29) in the Biotechnology industry is in the same range as XENE (37). This means that MRUS’s stock grew similarly to XENE’s over the last 12 months.

XENE's SMR Rating (94) in the Biotechnology industry is in the same range as MRUS (97). This means that XENE’s stock grew similarly to MRUS’s over the last 12 months.

MRUS's Price Growth Rating (79) in the Biotechnology industry is in the same range as XENE (83). This means that MRUS’s stock grew similarly to XENE’s over the last 12 months.

XENE's P/E Growth Rating (4) in the Biotechnology industry is significantly better than the same rating for MRUS (100). This means that XENE’s stock grew significantly faster than MRUS’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
MRUSXENE
RSI
ODDS (%)
Bullish Trend 2 days ago
89%
Bullish Trend 1 day ago
90%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
89%
Bullish Trend 1 day ago
84%
Momentum
ODDS (%)
Bearish Trend 2 days ago
73%
Bearish Trend 1 day ago
82%
MACD
ODDS (%)
Bearish Trend 2 days ago
86%
Bearish Trend 1 day ago
90%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
81%
Bearish Trend 1 day ago
77%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
79%
Bearish Trend 1 day ago
75%
Advances
ODDS (%)
Bullish Trend 15 days ago
84%
Bullish Trend 11 days ago
75%
Declines
ODDS (%)
Bearish Trend 3 days ago
79%
Bearish Trend 3 days ago
74%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
90%
Bullish Trend 1 day ago
86%
Aroon
ODDS (%)
Bullish Trend 2 days ago
79%
Bearish Trend 1 day ago
77%
View a ticker or compare two or three
Ad is loading...
MRUS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
XENE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
LDMIX13.60N/A
N/A
Lazard Developing Markets Equity Instl
HOVLX52.01N/A
N/A
Homestead Value
FDEGX63.01N/A
N/A
Fidelity Growth Strategies
EQIRX12.03N/A
N/A
Allspring Emerging Markets Eq Advtg R6
RSLDX64.68N/A
N/A
American Funds SMALLCAP World R5E

MRUS and

Correlation & Price change

A.I.dvisor indicates that over the last year, MRUS has been loosely correlated with CYTK. These tickers have moved in lockstep 35% of the time. This A.I.-generated data suggests there is some statistical probability that if MRUS jumps, then CYTK could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MRUS
1D Price
Change %
MRUS100%
-3.03%
CYTK - MRUS
35%
Loosely correlated
+0.67%
KRYS - MRUS
34%
Loosely correlated
-1.58%
CGON - MRUS
34%
Loosely correlated
-15.74%
VCYT - MRUS
34%
Loosely correlated
-5.51%
XENE - MRUS
33%
Loosely correlated
-2.48%
More